EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
NodThera Announces the Publication and Presentation of Cardiometabolic Clinical DataSupporting the Potential of Ruvonoflast to Treat Inflammation at the Source
Data published in the Journal of the American College of Cardiology Represents first peer-reviewed publication of clinical data demonstrating reductions in cardiometabolic risk
NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress
Boston, MA, May 19, 2026 – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to